Bunge Global vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
St. Louis global ag trader and processor (NYSE: BG) ~$45.8B FY2024 revenue; Viterra $8.2B acquisition pending 2025 closing, soybean crush/export, biofuel demand competing with ADM and Cargill.
About
Bunge Global SA is a St. Louis, Missouri-based agricultural commodities trader and food processing company — publicly traded on the New York Stock Exchange (NYSE: BG) as an S&P 500 Consumer Staples component, incorporated in Switzerland — processing oilseeds (soybeans, canola, sunflower) into vegetable oils and protein meals for food manufacturers, animal feed producers, and biodiesel refiners; trading grains and oilseeds globally through port elevators, inland grain terminals, and trading offices; and producing edible oils and specialty fats for consumer food brands through approximately 30,000 employees in 40+ countries. In fiscal year 2024, Bunge reported revenues of approximately $45.8 billion (declining from the 2022 commodity price peak as soybean crush margins normalized from supercycle levels), with adjusted EBITDA of approximately $1.5 billion from the Agribusiness, Refined Oils, and Milling segments. CEO Greg Heckman's defining strategic transaction: the pending acquisition of Viterra (Glencore's agricultural trading arm, formerly Viterra — handling grain, oilseed, and specialty crops origination and processing from Canada, Australia, and Europe) for $8.2 billion, announced in June 2023 and working through global competition authority approvals through 2024-2025 — creating a combined company with $60+ billion in combined revenues and market positions in North American, South American, European, and Australian grain origination that would rank alongside Archer-Daniels-Midland (ADM), Louis Dreyfus, and Cargill as a global agricultural trading leader. The Viterra combination (expected to close in mid-2025 after approval from EU, Canada, and Australia competition regulators) adds Viterra's Canadian canola origination (8+ million metric tons annually), Australian grain export infrastructure, and European oilseed and specialty crop handling to Bunge's Brazilian soy, US soybean, and Argentine origination platforms.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.